<DOC>
	<DOCNO>NCT01500161</DOCNO>
	<brief_summary>The purpose study evaluate multi-lineage hematopoietic chimerism unrelated umbilical cord blood ( UCB ) graft pool two three cord blood unit . Also evaluate toxicity , antitumor response pool unrelated UCB transplant .</brief_summary>
	<brief_title>Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match</brief_title>
	<detailed_description>Hematopoietic stem cell ( HSC ) transplantation , use human HLA-matched sibling unrelated bone marrow peripheral blood stem cell donor , use successfully treat patient high-risk relapsed hematologic malignancy . However , use therapy limited availability fully HLA-matched donor , despite increase size unrelated donor registry . For transplanted unrelated donor marrow stem cell , increase HLA disparity adversely affect survival due increase risk severe acute chronic graft-versus-host disease ( GVHD ) opportunistic infection . Only young recipient able tolerate single HLA-A , B , DRB1 mismatch setting ( 1-3 ) . To potentially extend donor pool , UCB use alternative source HSC . Since first unrelated donor UCB transplant 1993 , UCB transplant perform worldwide . It find produce outcome comparable match unrelated HSC patient hematologic malignancy ( 4 ) . It show cryopreserved unrelated UCB 0 3 HLA-A , B , DRB1-mismatched donor contain sufficient HSC engraft pediatrics adult patient ( 5-10 ) . Unfortunately , use UCB transplant limit small number HSC cord blood unit . This particularly problem adult patient . It possible pool UBC adequate cell number available adult transplant ( 11 ) . UBC rapidly availability low rate contamination herpes group viruses . UCB transplant result low incidence severe acute GVHD extensive chronic GVHD , despite use graft substantial donor-recipient HLA disparity ( 5-10 ) . The follow conditioning regimen use , depend underlie hematologic malignancy . Conditioning regimen Busulfan/clofarabine fludarabine/melphalan use patient except Non-Hodgkin 's lymphoma conditioning regimen BCNU , Etoposide , ARA-C Melphalan use . GVHD prophylaxis oral tacrolimus use , depend development GVHD clinical condition patient , tacrolimus may taper discontinue six month transplant . The hematopoietic stem cell donor infuse within 48-72 hour complete chemotherapy . The patient receive supportive care indicate include antibiotic , antiviral , antifungal , anti-seizure , anti-emetic medication medication necessary . In addition patient receive irradiate blood product support necessary.CMV negative recipient transplant receive CMV- blood product . Neutrophil engraftment define day ANC rise &gt; 500 cells/ml two consecutive day . Platelet engraftment define first day platelet count rise &gt; 20,000/ml 7-day interval without transfusion support .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients &lt; 65 year hematologic malignancy need stem cell transplant HLAmatched sibling donor . Patients follow diagnosis include : AML first subsequent complete partial remission ALL first subsequent complete partial remission CLL second remission advance disease CML fail tyrosine kinase inhibitor Hodgkin 's disease relapse autologous transplant NonHodgkin 's lymphoma relapse autologous transplant NKcell lymphoma CR1 Aplastic anemia patient Multiple myeloma second remission moer advance disease , include fail autologous transplant Myelodysplastic syndrome first subsequent complete partial remission Patients must 6/6 , 5/6 4/6 molecular match unrelated UCB donor . Matching do A , B , DR . Matching DR confirm molecular typing . Patients must document HIV negative . Screening must perform within previous 6 month . Patients must able give write consent . Patient exclude Inclusion criterion n't meet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Aplastic Anemia</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>CLL</keyword>
	<keyword>CML</keyword>
</DOC>